Incidence of catheter-related complications in patients with central venous or hemodialysis catheters: a health care claims database analysis

Abstract

BackgroundCentral venous catheter (CVC) and hemodialysis (HD) catheter usage are associated with complications that occur during catheter insertion, dwell period, and removal. This study aims to identify and describe the incidence rates of catheter-related complications in a large patient population in a United States-based health care claims database after CVC or HD catheter placement.MethodsPatients in the i3 InVision DataMart® health care claims database with at least 1 CVC or HD catheter insertion claim were categorized into CVC or HD cohorts using diagnostic and procedural codes from the US Renal Data System, American College of Surgeons, and American Medical Association’s Physician Performance Measures. Catheter-related complications were identified using published diagnostic and procedural codes. Incidence rates (IRs)/1000 catheter-days were calculated for complications including catheter-related bloodstream infections (CRBSIs), thrombosis, embolism, intracranial hemorrhage (ICH), major bleeding (MB), and mechanical catheter–related complications (MCRCs).ResultsThirty percent of the CVC cohort and 54% of the HD cohort had catheter placements lasting <90 days. Catheter-related complications occurred most often during the first 90 days of catheter placement. IRs were highest for CRBSIs in both cohorts (4.0 [95% CI, 3.7-4.3] and 5.1 [95% CI, 4.7-5.6], respectively). Other IRs in CVC and HD cohorts, respectively, were thrombosis, 1.3 and 0.8; MCRCs, 0.6 and 0.7; embolism, 0.4 and 0.5; MB, 0.1 and 0.3; and ICH, 0.1 in both cohorts. Patients with cancer at baseline had significantly higher IRs for CRBSIs and thrombosis than non-cancer patients. CVC or HD catheter–related complications were most frequently seen in patients 16 years or younger.ConclusionsThe risk of catheter-related complications is highest during the first 90 days of catheter placement in patients with CVCs and HD catheters and in younger patients (≤16 years of age) with HD catheters. Data provided in this study can be applied toward improving patient care.

A 4-arm randomized controlled pilot trial of innovative solutions for jugular central venous access device securement in 221 cardiac surgical patients

“…CVADs are commonly used medical devices in hospitals, with three million used in the United States of America (USA), and 250,000 in the UK each year alone [1,2]. In total, 25-30% of CVADs are reported to fail via dislodgement, blockage, breakage, thrombosis, or infection, resulting in premature device removal [3,4]. This adversely impacts patients" care through interrupted treatment (e.g.…”

A 15-year retrospective review of brake fluid exposures in children from a single poison center

“…Evidence suggests that fomepizole prevents the formation of both HEAA and DGA [17], and this case along with the physical properties of DEG suggests that hemodialysis represents a reasonable and effective therapy in the severely poisoned patient. Acute pediatric hemodialysis, however, is not readily available in most centers, and carries significant risks including bleeding and infection [18]. In addition, fomepizole is not readily available in all emergency departments, particularly in rural environments [19].…”

Life-saving vascular access in vascular capital exhaustion: single center experience in intra-atrial catheters for hemodialysis

“…With an intra-cardiac approach, infections, mechanical dysfunction and catheter thrombosis, which are the main causes of traditional HD catheter failure, 15 remain as causes of morbidity related to the IAC. Catheter-related infections, one of the major concerns with HD catheters, are infrequent in the IAC, comparing to other catheters locations.…”